VSTM2L is a promising therapeutic target and a prognostic soluble-biomarker in cholangiocarcinoma.

IF 2.9 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY BMB Reports Pub Date : 2024-07-01

Jungwhoi Lee, Woogwang Sim, Jungsul Lee, Jae-Hoon Kim

{"title":"VSTM2L is a promising therapeutic target and a prognostic soluble-biomarker in cholangiocarcinoma.","authors":"Jungwhoi Lee, Woogwang Sim, Jungsul Lee, Jae-Hoon Kim","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of the present study is to provide a rational background for silencing the V-set and transmembrane domain containing 2 like (VSTM2L) in consort with recognising soluble VSTM2L against cholangiocarcinoma. A therapeutic target against cholangiocarcinoma was selected using iterative patient partitioning (IPP) calculation, and it was verified by in vitro and in silico analyses. VSTM2L was selected as a potential therapeutic target against cholangiocarcinoma. Silencing the VSTM2L expression significantly attenuated the viability and survival of cholangiocarcinoma cells through blockade of the intracellular signalling pathway. In silico analysis showed that VSTM2L affected the positive regulation of cell growth in cholangiocarcinoma. Liptak's z value revealed that the expression of VSTM2L worsened the prognosis of cholangiocarcinoma patients. In addition, soluble VSTM2L was significantly detected in the whole blood of cholangiocarcinoma patients compared with that of healthy donors. Our report reveals that VSTM2L might be the potential therapeutic target and a soluble prognostic biomarker against cholangiocarcinoma. [BMB Reports 2024; 57(7): 324-329].</p>","PeriodicalId":9010,"journal":{"name":"BMB Reports","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11289506/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMB Reports","FirstCategoryId":"99","ListUrlMain":"","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of the present study is to provide a rational background for silencing the V-set and transmembrane domain containing 2 like (VSTM2L) in consort with recognising soluble VSTM2L against cholangiocarcinoma. A therapeutic target against cholangiocarcinoma was selected using iterative patient partitioning (IPP) calculation, and it was verified by in vitro and in silico analyses. VSTM2L was selected as a potential therapeutic target against cholangiocarcinoma. Silencing the VSTM2L expression significantly attenuated the viability and survival of cholangiocarcinoma cells through blockade of the intracellular signalling pathway. In silico analysis showed that VSTM2L affected the positive regulation of cell growth in cholangiocarcinoma. Liptak's z value revealed that the expression of VSTM2L worsened the prognosis of cholangiocarcinoma patients. In addition, soluble VSTM2L was significantly detected in the whole blood of cholangiocarcinoma patients compared with that of healthy donors. Our report reveals that VSTM2L might be the potential therapeutic target and a soluble prognostic biomarker against cholangiocarcinoma. [BMB Reports 2024; 57(7): 324-329].

微信好友朋友圈 QQ好友复制链接

本刊更多论文

VSTM2L 是胆管癌中一个很有前景的治疗靶点和预后可溶性生物标志物。

本研究的目的是提供一个合理的背景，通过识别可溶性 VSTM2L 来沉默类似 V 集和跨膜结构域的 2（VSTM2L），从而对抗胆管癌。通过迭代患者分区（IPP）计算筛选出了针对胆管癌的治疗靶点，并通过体外和硅学分析进行了验证。VSTM2L被选为胆管癌的潜在治疗靶点。通过阻断细胞内信号通路，抑制 VSTM2L 的表达可显著降低胆管癌细胞的活力和存活率。硅学分析表明，VSTM2L影响了胆管癌细胞生长的正向调节。Liptak's z 值显示，VSTM2L 的表达会恶化胆管癌患者的预后。此外，与健康献血者相比，胆管癌患者全血中可溶性 VSTM2L 的检出率更高。我们的报告显示，VSTM2L可能是胆管癌的潜在治疗靶点和可溶性预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMB Reports 生物-生化与分子生物学

CiteScore

5.10

自引率

7.90%

发文量

141

审稿时长

1 months

期刊介绍： The BMB Reports (BMB Rep, established in 1968) is published at the end of every month by Korean Society for Biochemistry and Molecular Biology. Copyright is reserved by the Society. The journal publishes short articles and mini reviews. We expect that the BMB Reports will deliver the new scientific findings and knowledge to our readers in fast and timely manner.